Novo Nordisk to acquire controlling stake in BIOCORP

Novo Nordisk entered exclusive negotiations to acquire a controlling stake in BIOCORP, a French medical device company, from main shareholder BIO JAG, representing 45.3% of share capital, at €35 per share. This will be followed by a mandatory tender offer for all remaining shares, valuing BIOCORP at approximately €154 million.

“Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP.”globenewswire.com

• 1 source
• globenewswire.comNovo Nordisk enters exclusive negotiations to acquire aNovo Nordisk A/SJun 5, 2023

Summarized from public sources; check the original articles before acting on it.